USC Norris Launches Breast Cancer Blood Test Trial
Researchers in Los Angeles are evaluating a new liquid biopsy test designed to detect breast cancer alongside mammograms.
Updated on Oct. 20, 2026 in Cancer
Live Poll
Would you rely on a new blood test as a secondary screen for breast cancer?
The USC Norris Comprehensive Cancer Center has launched a clinical trial to evaluate whether a new blood test can detect early-stage breast cancer. The test identifies cancer-associated cells and tumor-related vesicles in the bloodstream.
Why it matters
This trial aims to determine if the test can detect breast cancer earlier than mammograms alone, potentially catching the disease at more treatable stages. The study focuses on integrating this technology into existing screening protocols.
The clinical trial evaluates if a blood test detecting rare cancer-associated cells and extracellular vesicles can improve upon current standards for the 300,000 annual breast cancer cases diagnosed in the U.S.
The players
USC Norris Comprehensive Cancer Center
This facility is a leading cancer research and treatment institution located in Los Angeles that is hosting the clinical trial.
USC Michelson Center
The USC Michelson Center Convergent Science Institute in Cancer is the research hub where this specific liquid biopsy technology was developed.
The details
Developed at the USC Michelson Center, the test analyzes two blood samples taken from participants one year apart to check for signs of early-stage tumors. Researchers will compare these results against patient diagnoses to establish the accuracy of the blood-based screening method.
Timeline
Participants will have two blood samples collected one year apart.
The Big Picture
This trial represents a shift in oncology toward liquid biopsy technology, building on the diagnostic research pioneered at the USC Michelson Center Convergent Science Institute in Cancer.
The study is intended for research purposes and is not a replacement for traditional mammograms or biopsies. Participants will contribute to data that may eventually define future clinical standards for breast cancer screening.
The takeaway
Early detection remains the most effective tool in treating breast cancer, though blood tests are still considered experimental. Patients should continue to prioritize routine mammograms as recommended by their primary healthcare providers.
Further reading
Learn more about new diagnostic advancements in the Cancer section.
Live Poll
Would you rely on a new blood test as a secondary screen for breast cancer?
